Azico Biophore India is an API manufacturer based in India. It holds 12 active US drug master files across a filed portfolio of 12 molecules. Its filings concentrate with MINSA (CR) and CDSCO (India). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 5 September 2025 as VAI. Customs aggregates show $9.3M of exports covering 234 molecules to 36 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Anakapalli, India | 3010823443 |
| Molecule | Regulators | Docs |
|---|---|---|
| Dapagliflozin | US FDA | 2 |
| Levothyroxine | SFDA (Saudi Arabia), US FDA | 2 |
| Pantoprazole | US FDA | 2 |
| Empagliflozin | US FDA | 1 |
| Famotidine | US FDA | 1 |
| Isoprenaline | SFDA (Saudi Arabia) | 1 |
| Liothyronine Sodium | US FDA | 1 |
| Oseltamivir | US FDA | 1 |
| Permethrin | SFDA (Saudi Arabia) | 1 |
| Sildenafil | US FDA | 1 |
| Tadalafil | US FDA | 1 |
| Triclabendazole | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 4 | None |
| CDSCO (India) | 1 | None |
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $1.1M | 18 |
| 2025 | Not reported | $9.3M | 36 |
| 2024 | Not reported | $8.6M | 32 |
| 2023 | Not reported | $7.6M | 32 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Azico Biophore India comes back tiered against every other supplier able to file there.
Start for free